Peginterferon Alfa-2a plus Ribavirin vs Peginterferon Alfa-2b plus Ribavirin for Chronic Hepatitis C Virus Infection in HIV- Infected Patients J Berenguer.

Slides:



Advertisements
Similar presentations
Hepatitis web study Hepatitis web study Sofosbuvir + Peginterferon + Ribavirin in Genotype 2 or 3 LONESTAR-2 Phase 2 Treatment Experienced Lawitz E, et.
Advertisements

Hepatitis web study Hepatitis web study Peginterferon alfa-2b + Ribavirin in GT 1-6 (Flat versus Weight-Based Ribavirin Dosing) WINR Study Phase 3 Treatment.
Hepatitis web study Hepatitis web study Sofosbuvir + Ribavirin + Peginterferon in Genotypes 1-3 PROTON Phase 2 Treatment Naïve Lawitz E, et al. Lancet.
Hepatitis web study Hepatitis web study Telaprevir in Treatment Experienced GT-1 REALIZE (Study 216) Phase 3 Treatment Experienced Zeuzem S, et al. N Engl.
Hepatitis web study Hepatitis web study Peginterferon alfa-2b + Weight-based Ribavirin in HCV GT 2,3 Phase 4 Treatment Naïve, Chronic HCV Zeuzem S, et.
Hepatitis web study Hepatitis web study Telaprevir in Treatment Naïve GT-1 ADVANCE (Study 108) Phase 3 Treatment Naïve Jacobson IM, et. al. N Engl J Med.
Hepatitis web study Hepatitis web study Sofosbuvir + Peginterferon + Ribavirin in Genotypes 1,4,5,6 ATOMIC Phase 2 Treatment Naïve Kowdley K, et al. Lancet.
Hepatitis web study Hepatitis web study Daclatasvir + Sofosbuvir +/- Ribavirin in Genotypes 1-3 A Trial Phase 2a Treatment Naïve and Treatment.
Hepatitis web study Hepatitis web study Peginterferon alfa-2b + RBV versus Interferon alfa-2b RIBAVIC STUDY Phase 3 Treatment Naïve, Chronic HCV and HIV.
Hepatitis web study Hepatitis web study Simeprevir + PEG + RBV in Treatment-Naïve Genotype 1 QUEST-2 Trial Phase 3 Treatment Naïve Manns M, et al. Lancet.
Hepatitis web study Hepatitis web study Simeprevir + PEG + RBV in Treatment-Naïve Genotype 1 QUEST-1 Trial Phase 3 Treatment Naïve Jacobson IM, et al.
Hepatitis web study Hepatitis web study Peginterferon alfa-2a versus Interferon alfa-2a Phase 3 Treatment Naïve, Chronic HCV Zeuzem S, et al. N Engl J.
Hepatitis web study Hepatitis web study PEG alfa-2a + RBV versus PEG alfa-2a versus INF + RBV APRICOT STUDY Phase 3 Treatment Naïve, Chronic HCV and HIV.
Hepatitis web study Hepatitis web study Peginterferon alfa-2b + RBV vs. Peginterferon alfa-2a + RBV IDEAL STUDY Phase 3, Treatment Naïve Treatment Naïve,
Hepatitis web study Hepatitis web study Duration and Dose Finding Peginterferon alfa-2a + Ribavirin Phase 3 Treatment Naïve, Chronic HCV Randomized study.
Hepatitis web study Hepatitis web study Telaprevir in Treatment Naïve GT-1 ILLUMINATE (Study 111) Phase 3 Treatment Naïve Sherman KE, et. al. N Engl J.
Hepatitis web study Hepatitis web study Peginterferon alfa-2a + RBV versus Interferon alfa-2a + RBV ACTG 5071 Phase 2 Treatment Naïve, Chronic HCV and.
Hepatitis web study Hepatitis web study Peginterferon alfa-2b + Ribavirin versus Interferon alfa-2b + Ribavirin Phase 3 Treatment Naïve, Chronic HCV Manns.
Hepatitis web study Hepatitis web study Peginterferon alfa-2b + Ribavirin for 12 or 24 Weeks in GT 2,3 Phase 3 Treatment Naïve, Chronic HCV Mangia A, et.
Hepatitis web study Hepatitis web study Peginterferon alfa -2a+/- Ribavirin versus Interferon alfa-2b + Ribavirin Phase 3 Treatment Naïve, Chronic HCV.
Hepatitis web study Hepatitis web study Sofosbuvir + Ribavirin in HCV Recurrence Following Liver Transplantation Phase 2 Charlton M, et al. Gastroenterology.
Hepatitis web study Hepatitis web study WINR Study Flat versus Weight-Based Ribavirin Dosing Phase 3 Treatment Naïve, Chronic HCV Jacobson IM, et. al.
Hepatitis web study Hepatitis web study Interferon alfa-2b +/- Ribavirin for 24 or 48 weeks Phase 3 Treatment Naïve, Chronic HCV McHutchison JG, et al.
Stefan ZEUZEM.
Hepatitis web study Hepatitis web study Peginterferon alfa-2a +/- Ribavirin for Chronic HCV Phase 3 Treatment Naïve, Chronic HCV Fried MW, et. al. N Engl.
Treatment of Chronic Hepatitis C in HCV-HIV Infected Patients J Mallolas Infectious Diseases Service Hospital Clínic Barcelona.
Liver fibrosis regression after anti HCV therapy and the rate of death, liver-related death, liver- related complications, and hospital.
Hepatitis web study Hepatitis web study Boceprevir in Treatment Experienced RESPOND-2 Phase 3 Treatment Experienced Bacon BR, et al. N Engl J Med. 2011;364:
Hepatitis web study Hepatitis web study Telaprevir BID versus q8 in Treatment Naïve GT-1 OPTIMIZE (Study C211) Phase 3 Treatment Naïve Buti M, et al. Gastroenterology.
ATOMIC  Design  Objective –SVR 24 by ITT-analysis, detection of a 30% or 25% difference between two treatment groups, 2-sided significance level of 5%,
Hepatitis web study Hepatitis web study Ledipasvir-Sofosbuvir in GT1 or GT4 and HIV Coinfection ION-4 Phase 3 Treatment Naïve and Treatment Experienced.
Triglycerides,LDL cholesterol and HOMA score predict the virological response in HIV/HCV co-infected patients treated with Pegylated interferon alpha 2a.
Twice Weekly Peg-IFN-alpha-2a with Ribavirin Improves Early Viral Kinetics over Standard Therapy Among HIV/HCV Co-Infected African American Patients Alison.
SMV + PEG-IFN + RBV Open-label W12 W24* or W48* N = years Chronic HCV infection Genotype 4 Treatment-naïve or experienced with relapse or partial.
Randomisation* 2 : 1 Double blind *Randomisation was stratified on genotype (1a or 1b or other) and IL28B genotype (CC, CT or TT) N = 133 N = 260 W24W48.
Hepatitis web study H EPATITIS W EB S TUDY H EPATITIS C O NLINE Ribavirin (Copegus, Rebetol, Ribasphere) Prepared by: David Spach, MD and H. Nina Kim,
Hepatitis web study Hepatitis web study Peginterferon alfa-2b + Ribavirin in Blacks & Non-Hispanic Whites Phase 3 Treatment Naïve, Chronic HCV Muir AJ,
Distinct hepatitis C virus kinetics in HIV- infected patients treated with ribavirin plus either pegylated interferon α-2a or α-2b Eugenia Vispo, Pablo.
W24 ≥ 18 years Chronic HCV infection Genotype 1 Treatment naïve Early fibrosis to compensated cirrhosis No HBV or HIV co-infection N = 10 SOF + weight-based.
SOLAR-2 LDV/SOF + RBV Randomisation of the 7 groups 1 : 1 Open-label SOLAR-2 Study: LDV/SOF + RBV in decompensated and post-liver transplant with genotype.
SOLAR-1 LDV/SOF + RBV Randomisation* of the 7 groups 1 : 1 Open-label SOLAR-1 Study: LDV/SOF + RBV in advanced liver disease  Design W12W24 ≥ 18 years.
Hepatitis web study Hepatitis web study Sofosbuvir + RBV in Treatment-Naïve Genotypes 2,3 FISSION Trial* Phase 3 *Note: Published in NEJM in tandem with.
Asselah T. AASLD 2015, Abs OSIRIS  Design SMV + PEG-IFN + RBV Open label Chronic HCV infection Genotype 4 Treatment-naïve Mild to moderate fibrosis.
 Design Randomisation* 2 : 1 Double blind *Randomisation was stratified on genotype (1a vs 1b) and ILB28 genotype (CC or non-CC) N = 134 N = 257 W24W48.
 Design Open-label years Chronic HCV infection Genotype 1 HCV RNA > 10,000 IU/mL HIV co-infection Stable ART* with HIV RNA < 50 c/mL ≥ 24 weeks.
HAART Initiation Within 2 Weeks of Seroconversion Associated With Virologic and Immunologic Benefits Slideset on: Hecht FM, Wang L, Collier A, et al. A.
Hadziyannis SJ et al. EASL Peginterferon alfa-2a (40KD) (PEGASYS ® ) in combination with ribavirin (RBV): efficacy and safety results from a phase.
Previous SVR With Interferon-Based Therapy for HCV Lowers Risk of Hepatotoxicity in HIV/HCV-Coinfected Individuals on Antiretroviral Therapy Slideset on:
Maria Buti,1 Yoav Lurie,2 Natalia G. Zakharova,3 Natalia P. Blokhina,4 Andrzej Horban,5 Gerlinde Teuber,6 Christoph Sarrazin,6 Ligita Balciuniene,7 Saya.
Journal Conference Hepatology 2009;50: Background.
#AIDS2016 Dolutegravir (DTG) plus Rilpivirine (RPV) in Suppressed Heavily Pretreated HIV-Infected Patients A. Díaz, J.L. Casado, F.
Daclatasvir + Sofosbuvir +/- Ribavirin in Genotype 1-3 Trial
Phase 3 Treatment-Naïve and Treatment-Experienced
Phase 3 Treatment-Naïve and Treatment-Experienced
Phase 3 Treatment-Naïve and Treatment-Experienced
Phase 2 Treatment Naïve HIV Coinfection
Boceprevir in Treatment Naive SPRINT-2
Simeprevir in HIV Coinfection, GT-1 C212 Trial
Phase 3 Treatment Naïve HIV Coinfection
Ombitasvir + Paritaprevir + Ritonavir +/- Ribavirin in HCV GT4 PEARL-I
Phase 3 Treatment-Naïve and Treatment-Experienced
Daclatasvir + Peg/RBV in Treatment-Naïve Genotype 4 COMMAND-4 Study
Ledipasvir-Sofosbuvir +/- Ribavirin in HCV Genotype 1 ION-2
Ledipasvir-Sofosbuvir +/- Ribavirin for 8 or 12 weeks in HCV GT1 ION-3
ARV-trial.com TURQUOISE-I Study: ombitasvir/paritaprevir/ritonavir + dasabuvir + ribavirin for HCV in HIV co-infected patients Randomisation 1 : 1 Open-label.
Phase 3 Treatment-Naïve and Treatment-Experienced
Phase 3 Treatment-Naïve and Treatment-Experienced
CONCERTO-4 Study: SMV + PEG-IFNa-2b + RBV for genotype 1
Telaprevir + Peginterferon + Ribavirin for GT1 PROVE1 Study
Sequencing cohorts Open-label Design W8 W12 ≥ 18 years
Presentation transcript:

Peginterferon Alfa-2a plus Ribavirin vs Peginterferon Alfa-2b plus Ribavirin for Chronic Hepatitis C Virus Infection in HIV- Infected Patients J Berenguer *1, J González 2, J López-Aldeguer 3, MA Von-Wichman 4, C Quereda 5, F Pulido 6, J Sanz 7, C Tural 8, E Ortega 9, J Mallolas 10, I Santos 11, JM Bellón 1 and The GESIDA 3603 Study Group Hosp Gregorio Marañón, Madrid, Spain 1 ; Hosp La Paz, Madrid, Spain 2 ; Hosp La Fé, Valencia, Spain 3 ; Hosp Donostia, San Sebastián, Spain 4 ; Hosp Ramón y Cajal, Madrid, Spain 5 ; Hosp 12 de Octubre, Madrid, Spain 6 ; Hosp de Alcalá, Alcalá de Henares, Spain 7 ; Hosp Germans Trias i Pujol, Badalona, Spain 8 ; Hosp Clínico Universitario, Valencia, Spain 9 ; Hosp Clinic, Barcelona, Spain 10 ; and Hosp La Princesa, Madrid, Spain 11. J Berenguer *1, J González 2, J López-Aldeguer 3, MA Von-Wichman 4, C Quereda 5, F Pulido 6, J Sanz 7, C Tural 8, E Ortega 9, J Mallolas 10, I Santos 11, JM Bellón 1 and The GESIDA 3603 Study Group Hosp Gregorio Marañón, Madrid, Spain 1 ; Hosp La Paz, Madrid, Spain 2 ; Hosp La Fé, Valencia, Spain 3 ; Hosp Donostia, San Sebastián, Spain 4 ; Hosp Ramón y Cajal, Madrid, Spain 5 ; Hosp 12 de Octubre, Madrid, Spain 6 ; Hosp de Alcalá, Alcalá de Henares, Spain 7 ; Hosp Germans Trias i Pujol, Badalona, Spain 8 ; Hosp Clínico Universitario, Valencia, Spain 9 ; Hosp Clinic, Barcelona, Spain 10 ; and Hosp La Princesa, Madrid, Spain 11. Funding sources: Fundación para la Investigación y la Prevención del SIDA en España (FIPSE) (Ref /03) Funding sources: Fundación para la Investigación y la Prevención del SIDA en España (FIPSE) (Ref /03)

Background The most effective therapy for CHC in HIV+ patients is peg-IFN plus RBV 1-4. There are two approved brands of peg-IFN: peg-IFN  -2a (PEG2A) with a molecular weight of 40 kDa and peg-IFN  -2b (PEG2B) with a molecular weight of 12 kDa. –PEG2B has a larger Vd and higher renal clearance than PEG2A. –PEG2A is administered as a flat dose whereas PEG2B is administered according to body weight. It is unknown how these differences affect to sustained viral response (SVR) to therapy. 1)Torriani FJ, et al. N Engl J Med 2004;351(5): )Chung RT, et al. N Engl J Med 2004;351(5): )Carrat F, et al. JAMA 2004;292(23): )Laguno M, et al. AIDS 2004;18(13):F27-36.

Objective To compare the efficacy/safety of PEG2A-RBV and PEG2B-RBV against chronic HCV infection in HIV-infected patients.

Methods (I) Design Cohort study GESIDA 3603 Study Cohort Established to follow HIV/HCV+ patients who started IFN-RBV RX between Jan 2000 and Dec 2005 and with active follow-up every 6 mo. Primary objective: to determine the effect of achieving a SVR on long-term clinical outcomes including liver-related complications, and liver-related mortality. Secondary objetive: to assess the efficacy/safety of different IFN-RBV strategies Setting 11 clinical centers in Spain Patients For the purpose of this study we analyzed patients naïve for IFN who were treated with either PEG2A-RBV (N = 315) or PEG2B-RBV (N = 242).

Methods (II) Assessment End of treatment response (ETR): Undetectable HCV-RNA at the end of therapy with IFN-RBV SVR: Undetectable HCV-RNA 24 wk after the end of therapy with IFN-RBV Safety: Assessed by lab tests and evaluation of AE at least monthly during IFN- RBV therapy Statistics Differences between groups: Chi square, Student’s T or Mann Whitney-U as appropriate. Analyses were on an ITT and OT basis Logistic-regression models were used to explore baseline factors predicting an SVR and discontinuation of RX due to AE.

Patient characteristics (I)

Patient characteristics (II)

Treatment Details peg-IFN dose (given once weekly)1.5 ug/Kg180 μg RBV dose – mg/kg, median (IQR)13.3 (12.3; 14.7)14 (11.8; 15.7) Antiretroviral therapy– nº (%)

Treatment Response (All Genotypes) P = 0.02 ETR: End of Treatment Response. SVR: Sustained Virologic Response % P < 0.01 %

Treatment Response (According to Genotype) N = 127N = 156N = 19N = 37N = 9N = 8N = 76N = 99 N = 146N = 193N = 85N = 107 %

Sustained Virologic Response according to HCV Genotype and Baseline HCV RNA Level N = 37N = 51N = 96N = 125N = 32N = 33N = 50N = 60 %

Independent Factors Associated with a SVR by Multiple Logistic-Regression Analysis ORCI 95%p IFN PEG 2a + RBV 1.35(0.81; 2.26)0.250 CDC disease state (A/B vs C) 2.45(1.16;5.21)0.019 CD4 + cells nadir 1(1; 1)0.099 Current intake of > 50 EtOH daily 1.87(0.39;8.96)0.432 Fibrosis F3-F4 1.19(0.63; 2.22)0.595 HCV genotype (2.23; 6.36)<0.001 HCV-RNA ≥ 500 K IU/ml 1.27(0.74; 2.17)0.390 OR: Odds ratio. CI 95%: 95% Confidence Interval

Reason for interruption of Peg-IFN/RBV therapy

Dose Reductions and Discontinuation of Peg- IFN/RBV During Treatment

ART Adverse Events During Treatment

Deaths, HIV Disease Progression, Liver Decompensation

Conclusions No significant differences were found in efficacy/safety between PEG2A-RBV and PEG2B-RBV for the treatment of chronic HCV infection in HIV-infected patients